Biotech Values

[floblu14]

MNTA European/U.S. Patent Applications Update for RMF - Plus MNTA Overview of their Patent Estate -

1.POLYSACCHARIDE COMPOSITIONS AND METHODS OF USE FOR THE TREATMENT AND PREVENTION OF DISORDERS ASSOCIATED WITH PROGENITOR CELL MOBILIZATION 2014-01-23

Abstract:
Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20140123&CC=US&NR=2014024602A1&KC=A1

2.N-ACETYLHEXOSAMINE-CONTAINING N-GLYCANS IN GLYCOPROTEIN PRODUCTS 2014-01-22

Abstract not available

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=1&ND=3&adjacent=true&locale=en_EP&FT=D&date=20140122&CC=EP&NR=2686671A2&KC=A2

3.Methods of Evaluating Peptide Mixtures 2014-01-09

Abstract:
The presently disclosed subject matter provides methods for evaluating and characterizing peptides, peptide mixtures, and polypeptide mixtures. More particularly, the presently disclosed subject matter provides methods for evaluating or characterizing complex peptide or polypeptide mixtures comprising glutamic acid, alanine, tyrosine, and lysine, e.g., Copolymer-1 or glatiramer acetate, including, but not limited to, methods of identifying. isolating, quantifying, and purifying amino acids, peptides, polypeptides, and combinations thereof having a diethylamide group instead of a carboxyl group present on the C-terminus. The presently disclosed methods can be used to determine the mole percent of polypeptides having a diethylamide group at a C-terminus thereof and can be used to evaluate one or more properties of a sample of one polypeptide mixture as compared to one or more properties of a different sample of a polypeptide mixture

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=2&ND=3&adjacent=true&locale=en_EP&FT=D&date=20140109&CC=US&NR=2014011727A1&KC=A1

4. METHODS RELATED TO RITUXIMAB 2013-12-5

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131205&CC=WO&NR=2013181599A2&KC=A2

5. METHODS RELATED TO BEVACIZUMAB 2013-12-5

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=1&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131205&CC=WO&NR=2013181586A2&KC=A2

6.METHODS RELATED TO ADALIMUMAB 2013-12-5

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=2&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131205&CC=WO&NR=2013181585A2&KC=A2

7.METHODS RELATED TO OMALIZUMAB 2013-12-5

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=3&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131205&CC=WO&NR=2013181577A2&KC=A2

8.METHODS OF EVALUATING AND MAKING BIOLOGICS 2013-12-5

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=4&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131205&CC=WO&NR=2013181576A2&KC=A2

9.METHODS RELATED TO DENOSUMAB 2013-12-5

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=5&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131205&CC=WO&NR=2013181575A2&KC=A2

10. METHODS RELATED TO PANITUMUMAB 2013-12-5

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=6&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131205&CC=WO&NR=2013181572A2&KC=A2

Abstract:
The present disclosure provides methods for manufacturing or producing glatiramer acetate having a Mp of 5000-9000 Da. These methods include: polymerizing N-carboxy anhydrides of L-alanine, benzyl-protected L-glutamic acid, trifluoroacetic acid (TFA)-protected L-lysine, and L-tyrosine to generate a sample comprising intermediate-1; treating the sample comprising intermediate-1 to partially depolymerize the protected copolymer and deprotect benzyl-protected L-glutamic acid, measuring the viscosity of the sample comprising intermediate-1 during the treatment, and ending the treatment when the viscosity of the sample is within an endpoint range, thereby generating a sample comprising intermediate-2; treating the sample comprising intermediate-2 to deprotect TFA-protected L-lysine, thereby generating intermediate-3; further processing the intermediate-3 to generate a sample glatiramer acetate; and purifying the glatiramer acetate to generate a composition comprising purified glatiramer acetate having a Mp of 5000-9000 Da.

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=9&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131105&CC=US&NR=8575198B1&KC=B1

PATENTS

We license or own a patent portfolio of over 70 patent families, each of which includes United States patent applications and/or issued patents as well as foreign counterparts to certain United States patents and patent applications. Our patent portfolio includes issued or pending claims covering:

*Methods and technologies for characterizing polysaccharides and other heterogeneous mixtures

*The composition of matter and use of certain heparinases, heparinase variants and other enzymes

*Methods and technologies for synthesis of polysaccharides

*The composition of matter and use of certain novel low molecular weight heparin products, including M402

*Methods to identify, analyze and characterize glycoproteins

*Methods of manufacture of certain polysaccharide, polypeptide and complex protein or biologic products

http://www.momentapharma.com/technology/patents.php